What is Rani Therapeutics Holdings EBIT per Share?
Rani Therapeutics Holdings's EBIT per Share for the
three
months ended in Dec. 2024 was $-0.45.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.82.
During the past 3 years, the average EBIT per Share Growth Rate was 13.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -12.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Rani Therapeutics Holdings's EBIT per Share or its related term are showing as below:
RANI'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -43.2 Med: -22.6 Max: 13
Current: 13
During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Rani Therapeutics Holdings was 13.00% per year. The lowest was -43.20% per year. And the median was -22.60% per year.
RANI's 3-Year EBIT Growth Rate is ranked better than 57.11% of 1231
companies
in the Biotechnology industry
Industry Median: 7.1
vs RANI: 13.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.82
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rani Therapeutics Holdings (NAS:RANI) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Rani Therapeutics Holdings EBIT per Share Related Terms
Thank you for viewing the detailed overview of Rani Therapeutics Holdings's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RANI has been successfully added to your 